NCT00669318View on ClinicalTrials.gov

Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2014

Conditions
LeukemiaLymphoma
Interventions
BIOLOGICAL

alemtuzumab

BIOLOGICAL

rituximab

DRUG

pentostatin

DRUG

sargramostim

Trial Locations (3)

22908

University of Virginia Cancer Center, Charlottesville

55905

Mayo Clinic, Rochester

52242-1002

Holden Comprehensive Cancer Center at University of Iowa, Iowa City

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT00669318 - Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Biotech Hunter | Biotech Hunter